InterCure Announces 100,000th RESPeRATE Unit Sold
It took approximately four years to generate the first 50,000 unit salesof RESPeRATE, as clinical evidence, physician advocacy and consumer awarenessbegan to take hold following the OTC clearance of the device. The second50,000 units were sold in just 15 months. Growth is being driven throughincreased traction in the U.S. direct-to-consumer and online retail channels.
RESPeRATE has driven record volume through the world's leading e-commerceprovider, Amazon.com, providing insight into the brand's sales potentialwithin the retail environment. "RESPeRATE was among the top 100 items in ourhealth and personal care store this holiday season," said Brett Barrilleaux,senior buyer at Amazon.com. "The brand's growth this year underscores ourshoppers' desire for non-drug solutions in hypertension management."
"InterCure is experiencing robust growth in our core direct-to-consumerand online retail businesses. This reflects the growing consumer adoptionrate for the RESPeRATE device and will serve us well as we expand ourdistribution into chain drugstores," said Erez Gavish, president and CEO ofInterCure, manufacturer of the RESPeRATE device. "This year, we have been ableto lay a solid foundation for our next phase of growth. Our traditional DTCbusiness is healthier than it has ever been, and we have now assembled a worldclass consumer healthcare team to successfully launch into the retail market.This combination of momentum and expertise gives us great confidence as wehead into a time of rapid acceleration in 2008."
RESPeRATE(R) is FDA-cleared for over-the-counter sale and is the onlymedical device on the market clinically proven to lower blood pressure throughpaced breathing therapy. The device uses the body's natural tendency to followexternal rhythms, interactively guiding the user to effortlessly reduce theirbreathing rate to a "therapeutic zone" of less than 10 breaths per minute. Thebreathing exercises with RESPeRATE relax the constricted muscles surroundingthe small blood vessels, allowing the blood to flow more freely and yielding asignificant and lasting reduction of blood pressure within weeks.
About InterCure, Ltd.
InterCure, a medical device company, publicly traded on the Tel Aviv StockExchange (TASE: INCR) has become a leader in the growing Personal TherapeuticDevice category. Its broadly patented "device-guided breathing" technologyplatform enables a systematic reduction in sympathetic outflow of theautonomic nervous system. InterCure is successfully selling the world's firsthypertension treatment device, RESPeRATE(R), with more than 100,000 unitssold. With multiple published clinical studies, regulatory clearance in mostkey international markets (including FDA over-the-counter ("OTC") clearance inthe U.S., the European CE mark and the Chinese SDA among others) and arenowned scientific advisory board, RESPeRATE is rapidly becoming a part ofthe standard of care for the treatment of hypertension. (www.intercure.com)
This news release may contain forward-looking statements that are based onthe Company's current beliefs and assumptions and on information currentlyavailable to its management. Forward-looking statements involve known andunknown risks, uncertainties and other factors that may cause the Company'sactual results, performance or achievements to be materially dif
You May Also Like